Bladder cancer is the fourth most common cancers among men.1 There is a poor prognosis and 5-year survival rate of invasive bladder cancer.2 The risk for recurrence was significantly higher in patients with p53 nuclear accumulation3, 4 and abnormal pRb status.5 Recently, aggressive bladder cancer was reported to be associated with downregulation of coxsackie and adenovirus receptor (CAR),6, 7, 8 making it an interesting target for bladder cancer therapy. The gene discussed is TP53; the disease is urinary bladder carcinoma.